| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,820,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ALX Oncology Holdings is a holding company. Through its subsidiaries, Co. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on capabilities in protein engineering and oncology led by the CD47 blocker, evorpacept. Co.'s primary product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction and breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
16,400 |
16,400 |
16,400 |
| Total Buy Value |
$102,338 |
$152,109 |
$152,109 |
$152,109 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
122,000 |
138,548 |
152,059 |
158,283 |
| Total Sell Value |
$1,611,556 |
$1,856,531 |
$1,949,679 |
$2,018,581 |
| Total People Sold |
2 |
4 |
4 |
4 |
| Total Sell Transactions |
5 |
10 |
15 |
19 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lettmann Jason |
Director |
– • • |
2021-12-08 |
4 |
S |
$33.23 |
$1,411,871 |
I/I |
(42,458) |
304,131 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-11-22 |
4 |
S |
$36.77 |
$547,314 |
D/D |
(14,884) |
164,544 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-11-22 |
4 |
OE |
$4.08 |
$122,400 |
D/D |
30,000 |
179,428 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2021-10-19 |
4 |
AS |
$54.17 |
$906,714 |
D/D |
(16,700) |
444,598 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-10-18 |
4 |
AS |
$54.33 |
$400,793 |
D/D |
(7,229) |
9,331 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-10-18 |
4 |
OE |
$4.08 |
$29,494 |
D/D |
7,229 |
16,560 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-10-11 |
4 |
AS |
$60.79 |
$450,422 |
D/D |
(7,387) |
149,428 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2021-09-20 |
4 |
AS |
$73.78 |
$1,242,213 |
D/D |
(16,700) |
461,298 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-09-17 |
4 |
AS |
$77.84 |
$895,811 |
D/D |
(11,345) |
9,331 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-09-17 |
4 |
OE |
$4.08 |
$46,288 |
D/D |
11,345 |
20,676 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-09-16 |
4 |
AS |
$80.43 |
$114,695 |
D/D |
(1,426) |
9,331 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-09-16 |
4 |
OE |
$4.08 |
$5,818 |
D/D |
1,426 |
10,757 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-09-10 |
4 |
AS |
$76.45 |
$573,670 |
D/D |
(7,387) |
156,815 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-08-23 |
4 |
AS |
$70.86 |
$4,448,762 |
D/D |
(60,000) |
9,331 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-08-23 |
4 |
OE |
$4.08 |
$244,800 |
D/D |
60,000 |
69,331 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2021-08-19 |
4 |
AS |
$59.79 |
$1,023,340 |
D/D |
(16,700) |
477,998 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-08-17 |
4 |
AS |
$65.24 |
$662,299 |
D/D |
(10,000) |
9,331 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-08-17 |
4 |
OE |
$4.08 |
$40,800 |
D/D |
10,000 |
19,331 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-08-10 |
4 |
AS |
$64.20 |
$477,439 |
D/D |
(7,387) |
164,202 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-07-12 |
4 |
AS |
$54.86 |
$405,527 |
D/D |
(7,387) |
171,589 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2021-06-21 |
4 |
AS |
$58.06 |
$978,480 |
D/D |
(16,700) |
511,246 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-06-10 |
4 |
AS |
$59.80 |
$449,697 |
D/D |
(7,387) |
178,976 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2021-05-19 |
4 |
AS |
$54.20 |
$930,276 |
D/D |
(16,700) |
527,946 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-05-10 |
4 |
AS |
$61.12 |
$457,772 |
D/D |
(7,387) |
186,363 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2021-04-19 |
4 |
AS |
$56.42 |
$962,433 |
D/D |
(16,700) |
544,646 |
|
- |
|
107 Records found
|
|
Page 3 of 5 |
|
|
